Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy

奥比努图库单抗 医学 美罗华 内科学 钙调神经磷酸酶 氯霉素 膜性肾病 胃肠病学 临床终点 环磷酰胺 耐火材料(行星科学) 肿瘤科 外科 化疗 淋巴瘤 移植 临床试验 肾小球肾炎 物理 天体生物学
作者
Mingyue Xu,Yifeng Wang,Min Wu,Ruiying Chen,Wenqian Zhao,Mingxin Li,Chuan‐Ming Hao,Qionghong Xie
出处
期刊:Nephrology Dialysis Transplantation [Oxford University Press]
标识
DOI:10.1093/ndt/gfae230
摘要

Abstract Background Rituximab has been shown effective in patients with primary membranous nephropathy refractory to glucocorticoids plus cyclophosphamide (GC+CTX) or calcineurin inhibitors (CNIs), but the response rates remain limited. Compared with rituximab, obinutuzumab is a humanized anti-CD20 monoclonal antibody with greater B-cell depletion capacity. This study was performed to investigate the effectiveness of obinutuzumab compared to rituximab in treating patients with refractory primary membranous nephropathy. Methods A retrospective study was conducted at Huashan Hospital, Fudan University between January 1, 2015 and July 31, 2024, and included adult patients with primary membranous nephropathy who met the following criteria, 1) resistance to GC+CTX and/or calcineurin inhibitor (CNI) regimens, 2) dependence on CNIs, or 3) relapse within 1 year after CTX discontinuation. The patients subsequently received either obinutuzumab or rituximab. The primary endpoint was treatment response, which was defined as overall remission of nephrotic syndrome with no need for rescue therapy after obinutuzumab versus rituximab treatment. The secondary measures included immunological remission and safety profiles. Results Among the 51 participants, 20 received obinutuzumab and 31 received rituximab. The response rate was significantly greater in patients receiving obinutuzumab than in those receiving patients (90.0% vs. 38.7%, p<0.001) during a follow-up period of 24 (IQR, 10–34) months. Cox proportional hazards survival regression analysis also revealed the superior effectiveness of obinutuzumab (p<0.001). Immunological remission rates were higher in patients receiving obinutuzumab at both 3 months (75.0% vs. 20.0%, p<0.001) and 6 months (87.5% vs. 21.4%, p<0.001). The safety profiles of the two treatments were comparable. Among the 19 nonresponders treated with rituximab, 10 subsequently received obinutuzumab, and 8 achieved remission during a follow-up period of 20.0 (IQR, 18.5–22.3) months. Conclusion This retrospective study suggests that obinutuzumab is an effective treatment option for patients with primary membranous nephropathy refractory to GC+CTX, CNI, and rituximab regimens.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
易拉罐发布了新的文献求助10
刚刚
刚刚
Jasper应助张辉采纳,获得10
刚刚
忧虑的鹭洋完成签到 ,获得积分10
刚刚
Maer完成签到,获得积分10
刚刚
账户已注销应助yufu采纳,获得30
刚刚
1秒前
2秒前
科研通AI2S应助Anonymous采纳,获得10
2秒前
周周完成签到,获得积分10
3秒前
foxdaopo完成签到,获得积分10
3秒前
kytwenxian完成签到,获得积分10
3秒前
3秒前
jucy发布了新的文献求助30
4秒前
4秒前
wang完成签到,获得积分10
4秒前
彭于晏应助东山月采纳,获得10
4秒前
4秒前
新小pi发布了新的文献求助50
5秒前
wlgjr发布了新的文献求助10
6秒前
充电宝应助AAAA采纳,获得10
6秒前
zzz完成签到,获得积分10
6秒前
Candice发布了新的文献求助10
6秒前
陶醉觅夏发布了新的文献求助10
7秒前
易拉罐完成签到,获得积分10
7秒前
周学完成签到,获得积分10
7秒前
yufu完成签到,获得积分20
8秒前
聂学雨发布了新的文献求助10
8秒前
9秒前
wanci应助追寻的藏花采纳,获得10
9秒前
Huazilin完成签到,获得积分10
9秒前
feifan159完成签到,获得积分10
10秒前
天天快乐应助Luke采纳,获得10
10秒前
王新康发布了新的文献求助10
10秒前
酷波er应助hua喵喵喵采纳,获得10
11秒前
11秒前
zxj关注了科研通微信公众号
11秒前
陆未离完成签到 ,获得积分10
12秒前
闪闪书桃完成签到,获得积分10
13秒前
有思想完成签到,获得积分10
14秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
A Dissection Guide & Atlas to the Rabbit 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3134447
求助须知:如何正确求助?哪些是违规求助? 2785391
关于积分的说明 7771957
捐赠科研通 2441024
什么是DOI,文献DOI怎么找? 1297678
科研通“疑难数据库(出版商)”最低求助积分说明 625042
版权声明 600813